RLAYHealthcareMid-Cap
Relay Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Relay Therapeutics, Inc. (RLAY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are RLAY insiders buying or selling?
Relay Therapeutics, Inc. insiders reported 5 open-market buys ($2.2M) and 192 sells ($387.3M) across 197 Form 4 filings — a net selling position of $385.1M.
Source: SEC EDGAR Form 4
Key Statistics (as of Aug 28, 2026)
Total Form 4 filings
197
SEC EDGAR
Insider filers
11
Insider buys (5)
$2.2M
Insider sells (192)
$387.3M
Insider sentiment
Net sellingNet insider flow of $385.1M in net selling.
Recent RLAY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 4.5K | $20.03 | $90.3K |
| Aug 28, 2026 | SVF Pauling (Cayman) Ltd | 10% Owner | Sale | 6.0M | $19.40 | $116.4M |
| Aug 18, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $20.33 | $979.9K |
| Aug 18, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $19.74 | $349.7K |
| Jul 30, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 1.5K | $18.61 | $27.2K |
| Jul 30, 2026 | Peter Rahmer | Cheif Corporate Development Officer | Sale | 748 | $18.61 | $13.9K |
| Jul 30, 2026 | Donald A Bergstrom | President, R&D | Sale | 2.2K | $18.61 | $41.6K |
| Jul 8, 2026 | Donald A Bergstrom | President, R&D | Sale | 8.7K | $18.71 | $162.0K |
| Jul 8, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $19.58 | $943.7K |
| Jul 8, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $18.69 | $331.1K |
| Jul 2, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 50.0K | $19.09 | $954.5K |
| Jun 24, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 187.2K | $16.97 | $3.2M |
| Jun 24, 2026 | Donald A Bergstrom | President, R&D | Sale | 93.5K | $16.94 | $1.6M |
| May 14, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $12.86 | $227.8K |
| Apr 30, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 972 | $14.79 | $14.4K |
| Apr 30, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 753 | $14.79 | $11.1K |
| Apr 30, 2026 | Donald A Bergstrom | President, R&D | Sale | 1.5K | $14.79 | $22.0K |
| Apr 10, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 19.5K | $13.19 | $257.5K |
| Mar 11, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $10.06 | $178.2K |
| Jan 29, 2026 | Donald A Bergstrom | President, R&D | Sale | 21.6K | $7.72 | $166.7K |
| Jan 29, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 13.0K | $7.71 | $100.5K |
| Jan 29, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 15.5K | $7.71 | $119.6K |
| Jan 7, 2026 | Sanjiv Patel | President and CEO | Sale | 43.2K | $7.82 | $337.6K |
| Nov 4, 2025 | Sanjiv Patel | President and CEO | Sale | 62.1K | $7.00 | $434.5K |
| Oct 30, 2025 | Peter Rahmer | Chief Corporate Development Officer; Exhibit 24 - Power of Attorney | Sale | 40.5K | $7.40 | $299.9K |
Showing the 25 most recent of 197 Form 4 filings for Relay Therapeutics, Inc..
Most active RLAY insiders
- Donald A Bergstrom52 filings
- Thomas Catinazzo48 filings
- Brian Adams38 filings
- Peter Rahmer29 filings
- Sanjiv Patel17 filings
Ask anything about RLAY insider activity
Use Trabud's AI agent to query Relay Therapeutics, Inc.'s Form 4 history in plain English — "Show me RLAY CEO purchases this year" or compare it against any other ticker.
Open the AI agentRLAY insider trading FAQ
Are Relay Therapeutics, Inc. insiders buying or selling?
Across 197 SEC Form 4 filings, Relay Therapeutics, Inc. (RLAY) insiders reported 5 open-market purchases totaling $2.2M and 192 sales totaling $387.3M. That is a net selling position of $385.1M.
How many insiders trade RLAY stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Relay Therapeutics, Inc.. The most recent filing was accepted on Aug 28, 2026.
Where does Trabud get RLAY insider trading data?
All RLAY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.